India & Serum Institute of India

India: High TB burden country; SII is based in India; potential beneficiary of vaccine.

Serum Institute of India: Manufacturing partner investing over $100 million; strengthens its vaccine portfolio and global reach.

India: India approved its first dengue vaccine, addressing a major public health challenge. The country accounts for one-third of global dengue cases, and the vaccine could reduce disease burden and healthcare strain.

Serum Institute of India: Serum Institute of India is among the domestic manufacturers with dengue vaccine candidates in development, indicating potential future competition.

India: Home to Serum Institute of India, manufacturing vaccine doses. Its role is in vaccine production.

Serum Institute of India: Manufactured a stockpile of 620,000 doses of the Oxford vaccine candidate. Its manufacturing capacity is crucial for potential large-scale deployment.

India: India, along with the African Union, postponed the India-Africa Forum Summit due to the evolving health situation in parts of Africa, demonstrating the international repercussions of the Ebola outbreak.

Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.

Serum Institute of India: The Serum Institute of India is fast-tracking the development and production of a vaccine candidate targeting the Bundibugyo strain of Ebola, in collaboration with the University of Oxford and CEPI, to address the lack of an approved vaccine for this variant.